ZIM
IOVA icon

Zacks Investment Management’s Iovance Biotherapeutics IOVA Stock Holding History

Zacks Investment Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,849
Closed -$35.9K – 803
2025
Q2 		$35.9K Buy
20,849
+7,649
+58% +$19K ﹤0.01% 687
2025
Q1 		$44K Buy
+13,200
New +$68.1K ﹤0.01% 643
2017
Q4 		– Sell
-17,256
Closed -$134K – 610
2017
Q3 		$134K Buy
+17,256
New +$109K ﹤0.01% 560

Other funds holding IOVA

MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Zacks Investment Management's IOVA Position: Q3 2025 in Review

Zacks Investment Management sold out of Iovance Biotherapeutics (IOVA) in Q3 2025, closing a stake of 20,849 shares — an estimated $35.9K sold.

Zacks Investment Management first reported a position in IOVA in Q3 2017 and held it in 3 quarters. The position peaked at $134K in Q3 2017. 253 funds tracked by Wall St. Rank hold IOVA as of Q3 2025.

  • Zacks Investment Management reported no remaining Iovance Biotherapeutics position as of Q3 2025 after selling out during the quarter.
  • Zacks Investment Management sold 20,849 Iovance Biotherapeutics shares in Q3 2025, an estimated $35.9K.
  • Zacks Investment Management first reported a position in Iovance Biotherapeutics in Q3 2017 and held it in 3 quarters.
  • Zacks Investment Management's Iovance Biotherapeutics position peaked at $134K in Q3 2017.
  • 253 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2025.

Based on Zacks Investment Management's 13F filing for Q3 2025, filed 14 Nov 2025.